PTGX Stock Analysis: Buy, Sell, or Hold?
PTGX - Protagonist Therapeutics, Inc
$81.80
2.07 (2.60%)
▲
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 20, 2026
18d
Get Alerted When PTGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PTGX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: PTGX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$37.19
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$23.09
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PTGX is currently trading at $81.80, which is considered oversold relative to its 30-day fair value range of $81.02 to $86.95. From a valuation perspective, the stock is trading at a discount (Forward PE: 77.0) compared to its historical average (96.6). Remarkably, the market is currently pricing in an annual earnings decline of 7.3% over the next few years. This pessimistic expectation contrasts with the company's recent 351.3% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PTGX is in a strong uptrend. Immediate support is located at $77.69, while resistance sits at $85.50.
Market Sentiment: PTGX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $96.33 (+17.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PTGX is in a strong uptrend. Immediate support is located at $77.69, while resistance sits at $85.50.
Market Sentiment: PTGX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $96.33 (+17.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$81.02 -
$86.95
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
54.8%
Protect Your Profits
Holding PTGX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($96.33)
Fair Price Analysis
30-Day Fair Range
$81.02 -
$86.95
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$77.70
Resistance Level
$85.50
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
77.05
Wall Street Target
$96.33
(+17.8%)
Revenue Growth (YoY)
0.8%
Earnings Growth (YoY)
351.3%
Profit Margin
21.9%
Valuation Discount vs History
-7.3% cheaper
PE vs Historical
77.1 vs 96.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.3%
(market-implied from PE analysis)
1-Year Target
$75.83
(-7%)
2-Year Target
$70.29
(-14%)
3-Year Target
$65.16
(-20%)
3-Yr Target (if PE normalizes)
(PE: 77→97)
$81.69
(0%)
📈
Valuation based on Current Earnings
Forward PE: 26.39 | Forward EPS (Implied): $3.10
Bull Case
$98.77
(+21%)
Analyst growth 15.0%, PE expands to 27.7
Base Case
$81.80
(0%)
Market implied 0.0%, PE stable at 26.4
Bear Case
$62.58
(-24%)
Severe decline -15.0%, PE contracts to 23.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 77.1 to 96.6
Stabilization Target:
$102.55
(+25.4%)
PE Expansion Potential:
+25.4%
Last updated: February 01, 2026 3:54 PM ET
Data refreshes hourly during market hours. Next update: 4:54 PM
Data refreshes hourly during market hours. Next update: 4:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PTGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
William D Waddill
SELL
12000 shares
2025-10-10
William D Waddill
SELL
4000 shares
2025-09-22
William D Waddill
SELL
4000 shares
2025-08-27
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$213 | 57 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$13 | 63 BUY |
Advanced PTGX Option Strategies
Professional options setups generated by AI based on today's PTGX price and gamma walls.
